Overview

SLV213 Treatment in COVID-19 Patients

Status:
Not yet recruiting

Trial end date:
2021-10-01

Target enrollment:

Participant gender:

Summary

This Phase 2a trial recruits adult ambulatory patients who have been determined to be COVID-19 positive. The study drug SLV213 will be administered to examine its safety, tolerability and provide assessment of its effect on clinical symptoms of COVID-19. Blood samples will be taken pre-dose and at several time points post-dose for pharmacokinetic (PK) analysis.

Phase:

Phase 2

Details

Lead Sponsor:

Kenneth Krantz, MD, PhD

Collaborator:

FHI Clinical, Inc.